Ardelyx reaches the 'capstone' in their third-straight positive PhIII – but many questions still linger
Ardelyx has added what it’s calling the topper to the mound of Phase III evidence that its lead drug can help chronic kidney disease patients, although questions remain around side effects and how great an improvement the drug offers over the standard-of-care.
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
